<DOC>
	<DOCNO>NCT01891539</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) fifth common type cancer men seventh woman third common cause death cancer worldwide . The overall incidence HCC remain high develop country steadily rise industrialize country . TACE Doxorubicin-eluting bead ( DEB-TACE ) recently develop novel therapy option HCC . In order maximize therapeutic efficacy , doxorubicin-loaded bead develop deliver high dos chemotherapeutic agent prolong permanence within tumor . The comparison efficacy safety TACE drug-eluting microspheres comparison conventional TACE ( cTACE ) show response time progression group significantly high cTACE group . TACE drug-eluting microspheres thus appear feasible promising approach treatment HCC . This study 's purpose evaluate treatment efficacy , survival rate safety TACE use drug-eluting microspheres load doxorubicin unresectable hepatocellular carcinoma .</brief_summary>
	<brief_title>Observational Prospective Study Chemoembolization With Doxorubicin Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description>This study 's purpose ass treatment efficacy , survival rate safety TACE use drug-eluting microspheres load doxorubicin unresectable hepatocellular carcinoma . Study Design : Prospective observational study . Primary objective : To collect data tumor response administration drug-eluting microspheres preloaded doxorubicin . Secondary objective : To collect data survival rate , time progression , tolerability treatment , number treatment require achieve objective response improvement quality life . Treatment method : Day -1 Doxorubicin dose 35/50 mg/m2 charge onto 2 ml microspheres Pharmacy . It suggest dissolve Doxorubicin powder 2 ml contrast medium . The charging time microspheres least 30 minute . Day 0 : prehydration , antibiotic prophylaxis set therapeutic scheme appropriate analgesic prophylaxis ( 3-day duration ) previously report ( 17 ) Day +1 : Upon admittance radiology room , 1 vial tropisetron ( diluted 100ml physiological solution ) 1 vial morphine hydrochloride dilute 100 ml i.v . administer slow drip . One vial morphine hydrochloride dilute 100 ml i.v . repeat one hour procedure necessary also 6 hour . Tropisetron i.v . need . Intra-arterial premedication ( optional ) 1 vial verapamil dilute 4 ml normal saline solution follow 4 ml lidocaine . Tumor Infusion ( segment/s dominant disease ) Doxorubicin dose 35/50 mg/m2 preloaded 2 ml 70-150 µm M1 microspheres . A second tumor infusion allow lesion present ( daughter tumor ) , use Doxorubicin dose 35/50 mg/m2 preloaded 2 ml 70-150 µm M1 microspheres ( follow radiologist oncologist ' planning cure ) . Day +30 : The procedure repeat . Day +90 : In case response , third administration follow procedure repeat Evaluation response Response assess 30 , 90 180 day TACE , monitor tumor dimension use Chest-abdomen CAT scan without contrast medium , cancer marker ( CEA , Carbohydrate Antigen ( CA ) 19.9 ) Tumor response perform accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . Assessment quality life Assessment quality life alliative Performance Scale PPSv2 perform baseline visit 30 , 60 180 day treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Patients confirm diagnosis HCC 2 . Patient HCC suitable radical therapy resection , liver transplantation percutaneous therapy patient indicated therapy contraindication patient reject treatment 3 . Multinodular single nodular tumor 5cm 4 . Hypervascular lesion show contrast enhancement early stage contrast medium injection CT MRI . 5 . At least one unidimensional lesion measurable accord Modified RECIST criterion CTscan MRI 6 . No invasion blood vessel ( hepatic portal , hepatic vein ) bile duct 7 . Eastern Cooperative Oncology Group performance status 0 1 8 . Proper blood , liver , renal , heart functionality 9. 18 year old 10 . Expected survival 6 month 11 . Prior write consent 1 . Extrahepatic metastasis ( Any lymph nod measure ≥ 10mm along short axis ) 2 . Tumor burden involve 50 % liver 3 . History biliary tract repair endoscopic biliary tract treatment 4 . Clinically important refractory ascites pleural fluid 5 . Any contraindication hepatic embolization procedure 6 . Any contraindication doxorubicin administration 7 . Contrast medium allergy contraindicate angiography 8 . Acute active cardiac , hepatic renal disease 9 . Pregnant , nurse childbearing age woman men sexually active n't want ca n't contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatocellular carcinoma , doxorubicin , chemoembolization</keyword>
</DOC>